Mali's medicines regulator, a directorate of the Ministry of Health rather than a separate agency. It examines marketing authorisation dossiers, runs the essential medicines programme and pharmacovigilance, and evaluates clinical trial applications, which the minister then approves.
The NIH's ClinRegs profile for Mali, last reviewed in January 2026, summarises the decrees that govern the Direction de la Pharmacie et du Médicament: Decree 2011-753 places it under the Ministry of Health and Social Development, led by a director, with three divisions covering regulation of the pharmaceutical profession and marketing authorisation, quality assurance and the economics of medicines, and biomedical analysis laboratories. Its mission includes defining pharmaceutical regulations, examining and monitoring marketing authorisation dossiers, running national essential medicines programmes and pharmacovigilance, and reviewing clinical trial applications after an ethics committee has given its opinion; ClinRegs describes the evaluated application then going to the Minister of Health and Social Development for final approval. The coordinates are an approximate Bamako point.
WHO's list of regulators operating at maturity level 3 or 4, dated August 2026, does not include Mali. Mali signed the treaty establishing the African Medicines Agency on 29 October 2019 and ratified it on 12 May 2020. The Health Sciences and Disease study of 2022 describes the DPM passing validated needs for anticancer medicines from CHU du Point G to the Ministry for purchase from the Pharmacie Populaire du Mali.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/